Carlotta Palumbo1,2, Angela Pecoraro3,4, Sophie Knipper3,5, Giuseppe Rosiello3,6, Zhe Tian3, Shahrokh F Shariat7,8,9,10,11, Claudio Simeone2, Alberto Briganti6, Fred Saad3,12, Alfredo Berruti13, Alessandro Antonelli2, Pierre I Karakiewicz3,8. 1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada palumbo.carlotta@gmail.com. 2. Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy. 3. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada. 4. Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy. 5. Martini Klinik, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 6. Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy. 7. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 8. Department of Urology, Weill Cornell Medical College, New York, NY, U.S.A. 9. Department of Urology, University of Texas Southwestern, Dallas, TX, U.S.A. 10. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. 11. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. 12. Department of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada. 13. Medical Oncology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
Abstract
AIM: This study analyzed the effect of metastasectomy on overall mortality (OM) and perioperative outcomes in patients with metastatic renal cell carcinoma (mRCC) treated exclusively with targeted therapy. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database (2006-2015), Kaplan-Meier analyses and multivariable Cox regression models tested for OM. Using the National Inpatient Sample (NIS) database (2006-2015), complication rates and in-hospital mortality were evaluated. RESULTS: Within the SEER database, 437 (12.2%) out of 3,654 patients underwent metastasectomy. Metastasectomy was associated with lower OM risk (median survival 11 vs. 9 months, hazard ratio=0.83; p=0.002). Within the NIS database, 351 such patients were identified. Complications and in-hospital mortality were 55.0% and 4.6%, respectively. CONCLUSION: Metastasectomy in patients with mRCC treated exclusively with targeted therapy is associated with lower OM risk, however, based on short duration of expected survival. Complications and in-hospital mortality rates are not negligible. Copyright
AIM: This study analyzed the effect of metastasectomy on overall mortality (OM) and perioperative outcomes in patients with metastatic renal cell carcinoma (mRCC) treated exclusively with targeted therapy. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database (2006-2015), Kaplan-Meier analyses and multivariable Cox regression models tested for OM. Using the National Inpatient Sample (NIS) database (2006-2015), complication rates and in-hospital mortality were evaluated. RESULTS: Within the SEER database, 437 (12.2%) out of 3,654 patients underwent metastasectomy. Metastasectomy was associated with lower OM risk (median survival 11 vs. 9 months, hazard ratio=0.83; p=0.002). Within the NIS database, 351 such patients were identified. Complications and in-hospital mortality were 55.0% and 4.6%, respectively. CONCLUSION: Metastasectomy in patients with mRCC treated exclusively with targeted therapy is associated with lower OM risk, however, based on short duration of expected survival. Complications and in-hospital mortality rates are not negligible. Copyright
Authors: Giuseppe Rosiello; Sophie Knipper; Carlotta Palumbo; Cristina Dzyuba-Negrean; Angela Pecoraro; Elio Mazzone; Francesco A Mistretta; Zhe Tian; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2019-08-29 Impact factor: 2.370
Authors: Giuseppe Rosiello; Angela Pecoraro; Marina Deuker; Lara Franziska Stolzenbach; Thomas Martin; Zhe Tian; Alessandro Larcher; Umberto Capitanio; Francesco Montorsi; Shahrokh F Shariat; Anil Kapoor; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: Int J Clin Oncol Date: 2021-01-30 Impact factor: 3.402